Is the price fair?
What BIOA's price assumes
BioAge Labs, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 72.0× revenue.
72.0
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 1.96
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 1.96
- EV / EBIToperating margin −986%: the multiple describes the denominator
- not meaningful
- Market capitalisation
- $1.01B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - Specialty & Generic
The closest names by size in the same industry